HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Zoccali, C. Articles by Jager, K. Search for Related Content PubMed PubMed Citation Articles by Zoccali, C. Articles by Jager, K.

The Databases: Renal Replacement Therapy Since 1989—The European Renal Association and European Dialysis and Transplant Association (ERA-EDTA)

Carmine Zoccali^*, Anneke Kramer, and Kitty Jager

^* Nephrology and Renal Transplantation Unit and Consiglio Nazionale delle Ricerche, Instituto di Biomedicina, Ospedali Riuniti, Reggio Cal, Italy; and
ERA-EDTA Registry, Academic Medical Center, Department of Medical Informatics, Amsterdam, Netherlands

Correspondence: Dr. Carmine Zoccali, Nefrologia a CNR, Ospedali Riuniti, 89125 Reggio Cal, Italy. Phone: 0039 0965 397010; Fax: 0039 0965 397000; E-mail: carmine.zoccali{at}tin.it

Chronic kidney disease is now considered a public health priority, and the prevalence of this disease is approximately 10% in both North American and European countries. Such a phenomenon raises concern about the future increased incidence of ESRD. A recent analysis in the European Renal Association–European Dialysis and Transplant Association Registry shows that the incidence rates in Northern European countries have stabilized at approximately 110 per million people, a phenomenon that is associated with a parallel stabilization in the incidence of ESRD caused by diabetes. Such a stabilization has occurred in the face of an increasing prevalence of diabetes and hypertension in the general population, suggesting that this improvement may be the result of better prevention. Genetic factors, competing risks with other diseases, and other medical factors explain only in part the variability in the incidence of renal replacement therapy in European countries. Health care financing priorities have an obvious influence on the outcome of ESRD. Nonmedical factors seem to be of importance at least equal to that of medical factors. In this respect, Dialysis Outcomes and Practice Patterns Study Europe has revealed relevant differences in clinical policies that are related to ESRD treatment among European countries.